大肠癌组织人表皮生长因子受体2表达水平与患者临床病理特点及化疗效果的关系
|
摘要
目的探讨大肠癌组织人表皮生长因子受体2(Her-2)表达水平与患者临床病理特点及化疗效果的关系。方法选取2015年3月-2016年3月在本院就诊并确诊的大肠癌患者80例作为研究对象,所有患者均检测组织中Her-2基因的表达,探讨Her-2基因表达水平与大肠癌临床病理特点、化疗效果及临床预后的关系。结果大肠癌患者Her-2强阳性表达的患者TNM分期Ⅳ期9例、低分化13例、伴有淋巴结转移11例,与Her-2阴性表达、阳性表达的患者差异显著,Her-2阴性表达的患者CR、PR、SD、PD分别为9例、6例、3例、2例,缓解率明显高于阳性、强阳性组。Logistic回归模型分析提示,TNM分期、Her-2强阳性是大肠癌患者死亡的独立危险因素(P<0.05)。结论大肠癌组织中强Her-2表达是患者预后不良的独立危险因素。
Objective To investigate the relationship between the expression of human epidermal growth factor receptor 2 and the clinicopathological features,the effect of chemotherapy in colorectal carcinoma. Methods Eighty patients with colorectal cancer who were diagnosed in our hospital from March 2014 to March 2015 were selected as subjects. All patients were conducted for the test of Her-2 gene expression,and the relationship of Her-2 gene expression with pathological features,chemotherapy effects and clinical prognosis in colorectal cancer was explored. Results TNM staging of colorectal cancer patients with strong positive expression of Her-2 showed 9 cases of stage Ⅳ,13 cases of poor differentiation,and 11 cases of lymph node metastasis,and the differences were significant compared with the patients with negative expression or positive expression of Her-2. There were 9 cases of CR,6 cases of PR,3 cases of SD,and 2 cases of PD in patients with negative Her-2,respectively. The remission rate was significantly higher than that of the positive group and the strong positive group. Logistic regression model analysis indicated that TNM and Her-2 strong positive were independent risk factors for death in colorectal cancer patients( P < 0. 05). Conclusion The expression of moderate and strong Her-2 in colorectal cancer is an independent risk factor for poor prognosis.
Objective To investigate the relationship between the expression of human epidermal growth factor receptor 2 and the clinicopathological features,the effect of chemotherapy in colorectal carcinoma. Methods Eighty patients with colorectal cancer who were diagnosed in our hospital from March 2014 to March 2015 were selected as subjects. All patients were conducted for the test of Her-2 gene expression,and the relationship of Her-2 gene expression with pathological features,chemotherapy effects and clinical prognosis in colorectal cancer was explored. Results TNM staging of colorectal cancer patients with strong positive expression of Her-2 showed 9 cases of stage Ⅳ,13 cases of poor differentiation,and 11 cases of lymph node metastasis,and the differences were significant compared with the patients with negative expression or positive expression of Her-2. There were 9 cases of CR,6 cases of PR,3 cases of SD,and 2 cases of PD in patients with negative Her-2,respectively. The remission rate was significantly higher than that of the positive group and the strong positive group. Logistic regression model analysis indicated that TNM and Her-2 strong positive were independent risk factors for death in colorectal cancer patients( P < 0. 05). Conclusion The expression of moderate and strong Her-2 in colorectal cancer is an independent risk factor for poor prognosis.
引文
[1]张亮,刘百歌,高申,等.大肠癌患者血清中Periostin蛋白含量的研究[J].中国实验诊断学,2015,19(4):637-638.
[2]胡小苗,李明忠.大肠癌组织中miRNA-21表达水平及其与预后的研究[J].中国普通外科杂志,2014,23(12):1717-1720.
[3]王士娜,王星,王翠芳.表皮生长因子受体及HER-2/neu蛋白在胃癌中的表达和意义[J].中国医科大学学报,2015,44(9):829-832.
[4]马莹,宋印利,包颖,等.EGFR、HER-2、VEGF及IGF-1R在胃癌组织中的表达及其与临床病理参数相关性分析[J].哈尔滨医科大学学报,2014,48(3):191-194.
[5]曹杰,储晶,周俭,等.联合应用参一胶囊对晚期大肠癌化疗效果的影响及安全性评价[J].世界临床医学,2016,10(20):29-30.
[6]李竟长,倪秉强,蒋志雄,等.精氨酸增强的肠外营养对晚期大肠癌化疗患者免疫功能及肠黏膜免疫屏障的影响[J].中国老年学杂志,2015,35(10):2717-2719.
[7]徐晓卿,齐元富.益气和血法治疗大肠癌患者化疗所致神经毒性疗效分析[J].世界中西医结合杂志,2014,9(10):1087-1089.
[8]王霞.内镜活检胃癌组织中HER-2蛋白表达及临床意义[J].现代消化及介入诊疗,2017,22(3):307-310.
[9]连欢,胡静,严文跃,等.结直肠癌HER-2表达水平与临床病理特征及预后的相关性[J].现代肿瘤医学,2017,25(11):1747-1751.
[10]曲福杰,潘立明,孙抒,等.Her-2及CA19-9在结直肠癌组织中的表达及临床意义[J].山东医药,2014,54(28):44-46.
[11]顾国青,费素娟,刘佳,等.胃癌组织中MMP-9及HER-2表达与患者临床病理及预后的关系[J].胃肠病学和肝病学杂志,2016,25(11):1236-1240.
[12]刘英,黄建军.乳腺癌新辅助化疗前后ER、PR、HER-2、EGFR、CK5/6的表达及预测化疗效果的意义[J].贵阳医学院学报,2014,39(5):682-687.
[13]张红涛.HER-2过表达型乳腺癌中Ki-67抗原表达状况及其疗效观察[D].乌鲁木齐:新疆医科大学,2015.
[14]叶新青,蒋奕,刘鹏,等.乳腺癌蒽环类药物化疗疗效与TOPOⅡα、HER-2的关系[J].诊断病理学杂志,2015,22(1):38-40,44.
[15]董亮,钱震,施蓉蓉,等.结直肠腺癌组织中p53、HER-2和Ki-67的表达及其临床病理意义[J].诊断病理学杂志,2015,22(1):19-22,26.
[2]胡小苗,李明忠.大肠癌组织中miRNA-21表达水平及其与预后的研究[J].中国普通外科杂志,2014,23(12):1717-1720.
[3]王士娜,王星,王翠芳.表皮生长因子受体及HER-2/neu蛋白在胃癌中的表达和意义[J].中国医科大学学报,2015,44(9):829-832.
[4]马莹,宋印利,包颖,等.EGFR、HER-2、VEGF及IGF-1R在胃癌组织中的表达及其与临床病理参数相关性分析[J].哈尔滨医科大学学报,2014,48(3):191-194.
[5]曹杰,储晶,周俭,等.联合应用参一胶囊对晚期大肠癌化疗效果的影响及安全性评价[J].世界临床医学,2016,10(20):29-30.
[6]李竟长,倪秉强,蒋志雄,等.精氨酸增强的肠外营养对晚期大肠癌化疗患者免疫功能及肠黏膜免疫屏障的影响[J].中国老年学杂志,2015,35(10):2717-2719.
[7]徐晓卿,齐元富.益气和血法治疗大肠癌患者化疗所致神经毒性疗效分析[J].世界中西医结合杂志,2014,9(10):1087-1089.
[8]王霞.内镜活检胃癌组织中HER-2蛋白表达及临床意义[J].现代消化及介入诊疗,2017,22(3):307-310.
[9]连欢,胡静,严文跃,等.结直肠癌HER-2表达水平与临床病理特征及预后的相关性[J].现代肿瘤医学,2017,25(11):1747-1751.
[10]曲福杰,潘立明,孙抒,等.Her-2及CA19-9在结直肠癌组织中的表达及临床意义[J].山东医药,2014,54(28):44-46.
[11]顾国青,费素娟,刘佳,等.胃癌组织中MMP-9及HER-2表达与患者临床病理及预后的关系[J].胃肠病学和肝病学杂志,2016,25(11):1236-1240.
[12]刘英,黄建军.乳腺癌新辅助化疗前后ER、PR、HER-2、EGFR、CK5/6的表达及预测化疗效果的意义[J].贵阳医学院学报,2014,39(5):682-687.
[13]张红涛.HER-2过表达型乳腺癌中Ki-67抗原表达状况及其疗效观察[D].乌鲁木齐:新疆医科大学,2015.
[14]叶新青,蒋奕,刘鹏,等.乳腺癌蒽环类药物化疗疗效与TOPOⅡα、HER-2的关系[J].诊断病理学杂志,2015,22(1):38-40,44.
[15]董亮,钱震,施蓉蓉,等.结直肠腺癌组织中p53、HER-2和Ki-67的表达及其临床病理意义[J].诊断病理学杂志,2015,22(1):19-22,26.